March 29, 2023
Evonik breaks ground on $220 million Lipid Innovation Center in Lafayette, Indiana
- Secures U.S-made key pharmaceutical excipients for RNA-based therapies for innovative medicines and pandemic preparedness
- Cooperative agreement with U.S. Government, with support from Indiana Economic Development Corporation, Greater Lafayette Commerce, and Duke Energy
- More than 80 highly skilled jobs in Greater Lafayette region
About Evonik
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.
Disclaimer
The Army Contracting Command – Aberdeen Proving Ground – COVID Response is the awarding and administering acquisition office. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the JPEO-CBRND, through the Industrial Base Expansion program under cooperative agreement number W58P05-22-2-0006. Opinions, interpretations, conclusions and recommendations are those of the author and do not imply or constitute DOD or U.S. government endorsement.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations, or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations, or statements contained in this release.
The Army Contracting Command – Aberdeen Proving Ground – COVID Response is the awarding and administering acquisition office. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the JPEO-CBRND, through the Industrial Base Expansion program under cooperative agreement number W58P05-22-2-0006. Opinions, interpretations, conclusions and recommendations are those of the author and do not imply or constitute DOD or U.S. government endorsement.
Online version press release